RecruitingPhase 4NCT06684743
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above
Sponsor
Tor Biering-Sørensen
Enrollment
690,000 participants
Start Date
Nov 18, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Age 18 years and above
- Informed consent form has been signed and dated
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALRSV prefusion F protein-based vaccine
For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06684743
Related Trials
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
NCT070970124 locations
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
NCT061601281 location
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
NCT071475172 locations
SURVEILLANCE, ASSESSMENT AND DETECTION OF INFLUENZA ASSOCIATED RESPIRATORY INFECTIONS IN HIV POSITIVE AND NEGATIVE INDIVIDUALS IN LUSAKA, ZAMBIA
NCT070300752 locations
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
NCT066726923 locations